Histogen Inc. HSTO
Set alert
0.02 0.00 0.00%
As of Nov 25, 3:00 PM ET
0.02 Day range 0.02
52-week range unavailable
- Open
- 0.00
- Prev close
- 0.02
- Mkt cap
- 3.38M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.02
- High
- 0.02
- Forward P/E
- -0.19
- Beta
- 0.97
- Short ratio
- 0.45
- Inst. own
- 7.79%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 14, 2024
- 50-d avg
- 0.8226
- 200-d avg
- 1.03
- 1y target
- 2.00
Key statistics
- Market cap
- 3.38M
- Enterprise value
- -2.42M
- Trailing P/E
- 0.75
- Forward P/E
- -0.19
- PEG ratio
- -0.01
- Price / sales
- 177.84
- Price / book
- 0.30
- EPS (TTM)
- 1.06
- Beta
- 0.97
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 19.00K
- Revenue growth
- -99.90%
- Free cash flow
- -2.31M
- Total cash
- 9.66M
- Total debt
- 4.58M
- Return on equity
- -78.38%
- Shares outstanding
- 4.27M
- Short % of float
- 0.37%
- 50-day average
- 0.8226
- 200-day average
- 1.03
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 2.00
Next earnings
Nov 14, 2024
Expected Nov 14, 2024. Consensus EPS estimate -0.90.
Financials — quick view
HSTO Revenue — quarterly 5.00K
HSTO Net income — quarterly -2.09M
HSTO EPS — quarterly -0.49
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Oct 3, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 4, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 29, 2022 | HC Wainwright & Co. | main | — | Buy |
| Aug 30, 2021 | HC Wainwright & Co. | init | — | Buy |
| Jun 4, 2021 | Canaccord Genuity | main | — | Buy |
| Mar 4, 2021 | Canaccord Genuity | init | — | Buy |
About Histogen Inc.
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- histogen.com
News
- Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering
- Histogen Announces Second Adjournment of Special Meeting of Stockholders
- Histogen Announces Adjournment of Special Meeting of Stockholders
- Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- Stocks That Hit 52-Week Lows On Tuesday
- Histogen Announces Board Approval of Complete Liquidation and Dissolution
- Stocks That Hit 52-Week Lows On Thursday
- Why Sidus Space Shares Are Trading Lower By Around 24%; Here Are 20 Stocks Moving Premarket
- Why Chicken Soup For The Soul Entertainment Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
- Top Sectors to Explore for Penny Stocks to Buy
Your note
Sign in to keep a note on HSTO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CASHION CHARLES J | Chief Financial Officer | Conversion of Exercise of derivative security | Jan 8, 2017 | 187,162 |
| KISNER DANIEL L | Director | Purchase | Apr 7, 2015 | 7,145 |
| MARSHALL KEITH W. | Chief Operating Officer | Conversion of Exercise of derivative security | May 21, 2020 | 19,885 |
| MENTO STEVEN J | Director | Conversion of Exercise of derivative security | May 21, 2020 | 82,280 |
| PASCOE RICHARD W | Chief Executive Officer | Purchase | Mar 29, 2021 | 30,000 |
| RIPLEY DANIEL L. | Officer | Stock Award(Grant) | Nov 13, 2018 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 1.41% | 60,166 | 47.59K | Mar 30, 2023 |
| Blackrock Inc. | 0.82% | 34,910 | 27.61K | Mar 30, 2023 |
| Millennium Management Llc | 0.62% | 26,536 | 20.99K | Mar 30, 2023 |
| Susquehanna International Group, LLP | 0.36% | 15,487 | 12.25K | Mar 30, 2023 |
| Two Sigma Securities, LLC | 0.30% | 12,823 | 10.14K | Mar 30, 2023 |
| Geode Capital Management, LLC | 0.24% | 10,387 | 8.22K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.32% | 13,638 | 10.79K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.16% | 7,001 | 5.54K | Feb 27, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 2,611 | 2.06K | Feb 27, 2023 |
| Fidelity Series Total Market Index Fund | 0.01% | 612 | 484 | Feb 27, 2023 |
| Fidelity Total Market Index Fund | 0.00% | 128 | 101 | Feb 27, 2023 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.00% | 67 | 52 | Feb 27, 2023 |